Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Glaxo SmithKline

Novartis building

Novartis says pipeline is “industry leading”

Touts 14 drug candidates with $1bn-plus sales potential

- PMLiVE

Interview: Trevor Smith, Takeda

Takeda’s head of commercial operations for Europe and Canada talks about the integration of Nycomed and European market access

Novartis building

Novartis’ heart failure drug serelaxin meets targets

And FDA committee backs Signifor for Cushing's disease

Pharma deals during October 2012

As pharma companies ramp up their activity after the summer, this month's dealmakers included Pfizer, AstraZeneca, Merck & Co and Bayer

Bristol-Myers Squibb (BMS) building

BMS cuts salesforce on revised Abilify deal

Nearly 500 jobs to go as US rights to schizophrenia blockbuster return to Otsuka

- PMLiVE

Takeda acquires US-based drug discovery company Envoy

Japanese pharma firm gains target identification technology and preclinical CNS assets

Novartis building

EC approves extra tumour indication for Novartis’ Votubia

First drug approved in Europe for non-cancer tumours associated with TSC

Novartis building

Canada and Switzerland lift Novartis flu vaccines ban

Independent tests confirm safety following contamination fears

- PMLiVE

Discounts persuade NICE to recommend skin cancer drugs Yervoy and Zelboraf

Roche and BMS offer patient access schemes for NHS use of drugs

- PMLiVE

Novartis revives delayed Singapore biotech plans

Aims to have biotechnology facility up and running before 2017

- PMLiVE

GSK sales drop as austerity measures hit business in Europe

Revenues in region drop 9 per cent

- PMLiVE

Acquisitions soften Actos blow in Takeda’s first-half results

URL Pharma and Nycomed purchases help sales increase 12 per cent to 787bn yen

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links